TXK抗体—艾普蒂

+ +

•  

   

     Western blot analysis using TXK mouse mAb against  HeLa lysate    

  
  

The TXK antibody targets the TXK protein (also known as RLK), a non-receptor tyrosine kinase belonging to the Tec family. Primarily expressed in T lymphocytes and natural killer (NK) cells, TXK plays a critical role in T-cell receptor (TCR) signaling and immune regulation. Structurally, it contains a pleckstrin homology (PH) domain, SH3 and SH2 domains, and a catalytic kinase domain, enabling interactions with signaling molecules like PLCγ1 and Vav1. TXK activation contributes to cytokine production, cell proliferation, and differentiation, influencing both adaptive and innate immune responses.

Research links TXK dysfunction to autoimmune diseases, including multiple sclerosis, rheumatoid arthritis, and systemic lupus erythematosus (SLE). Overactive TXK signaling may drive pathogenic T-cell hyperactivity and inflammatory cytokine release. Consequently, TXK antibodies have emerged as investigative tools and potential therapeutic agents. In preclinical studies, anti-TXK antibodies inhibit kinase activity, suppress T-cell activation, and ameliorate autoimmune symptoms in animal models. Their clinical relevance is under exploration, particularly for targeted immunotherapy in autoimmune conditions. However, challenges remain in optimizing specificity and minimizing off-target effects. Current studies focus on elucidating TXK's role in disease mechanisms and validating its therapeutic potential through antibody-mediated modulation.